Literature DB >> 33408775

The 2020 race towards SARS-CoV-2 specific vaccines.

Tomasz M Karpiński1, Marcin Ożarowski2, Agnieszka Seremak-Mrozikiewicz3,4,5, Hubert Wolski3,6, Donald Wlodkowic7.   

Abstract

The global outbreak of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlighted a requirement for two pronged clinical interventions such as development of effective vaccines and acute therapeutic options for medium-to-severe stages of "coronavirus disease 2019" (COVID-19). Effective vaccines, if successfully developed, have been emphasized to become the most effective strategy in the global fight against the COVID-19 pandemic. Basic research advances in biotechnology and genetic engineering have already provided excellent progress and groundbreaking new discoveries in the field of the coronavirus biology and its epidemiology. In particular, for the vaccine development the advances in characterization of a capsid structure and identification of its antigens that can become targets for new vaccines. The development of the experimental vaccines requires a plethora of molecular techniques as well as strict compliance with safety procedures. The research and clinical data integrity, cross-validation of the results, and appropriated studies from the perspective of efficacy and potently side effects have recently become a hotly discussed topic. In this review, we present an update on latest advances and progress in an ongoing race to develop 52 different vaccines against SARS-CoV-2. Our analysis is focused on registered clinical trials (current as of November 04, 2020) that fulfill the international safety and efficacy criteria in the vaccine development. The requirements as well as benefits and risks of diverse types of SARS-CoV-2 vaccines are discussed including those containing whole-virus and live-attenuated vaccines, subunit vaccines, mRNA vaccines, DNA vaccines, live vector vaccines, and also plant-based vaccine formulation containing coronavirus-like particle (VLP). The challenges associated with the vaccine development as well as its distribution, safety and long-term effectiveness have also been highlighted and discussed. © The author(s).

Entities:  

Keywords:  COVID-19; SARS-CoV-2; clinical trials; coronavirus disease 2019; severe acute respiratory syndrome coronavirus 2; vaccine

Mesh:

Substances:

Year:  2021        PMID: 33408775      PMCID: PMC7778607          DOI: 10.7150/thno.53691

Source DB:  PubMed          Journal:  Theranostics        ISSN: 1838-7640            Impact factor:   11.556


  69 in total

1.  Lack of herd immunity against measles in individuals aged <35 years could explain re-emergence of measles in Catalonia (Spain).

Authors:  Pedro Plans; Nuria Torner; Pere Godoy; Mireia Jané
Journal:  Int J Infect Dis       Date:  2013-10-29       Impact factor: 3.623

2.  Is the drought over for pharming?

Authors:  Jocelyn Kaiser
Journal:  Science       Date:  2008-04-25       Impact factor: 47.728

Review 3.  SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.

Authors:  Prasun K Datta; Fengming Liu; Tracy Fischer; Jay Rappaport; Xuebin Qin
Journal:  Theranostics       Date:  2020-06-12       Impact factor: 11.556

Review 4.  A Comparison of Plasmid DNA and mRNA as Vaccine Technologies.

Authors:  Margaret A Liu
Journal:  Vaccines (Basel)       Date:  2019-04-24

5.  Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target.

Authors:  Haibo Zhang; Josef M Penninger; Yimin Li; Nanshan Zhong; Arthur S Slutsky
Journal:  Intensive Care Med       Date:  2020-03-03       Impact factor: 17.440

6.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.

Authors:  Daniel Wrapp; Nianshuang Wang; Kizzmekia S Corbett; Jory A Goldsmith; Ching-Lin Hsieh; Olubukola Abiona; Barney S Graham; Jason S McLellan
Journal:  Science       Date:  2020-02-19       Impact factor: 47.728

Review 7.  The clinical development process for a novel preventive vaccine: An overview.

Authors:  K Singh; S Mehta
Journal:  J Postgrad Med       Date:  2016 Jan-Mar       Impact factor: 1.476

Review 8.  Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections.

Authors:  Leroy Versteeg; Mashal M Almutairi; Peter J Hotez; Jeroen Pollet
Journal:  Vaccines (Basel)       Date:  2019-09-20

9.  Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.

Authors:  Denis Y Logunov; Inna V Dolzhikova; Olga V Zubkova; Amir I Tukhvatullin; Dmitry V Shcheblyakov; Alina S Dzharullaeva; Daria M Grousova; Alina S Erokhova; Anna V Kovyrshina; Andrei G Botikov; Fatima M Izhaeva; Olga Popova; Tatiana A Ozharovskaya; Ilias B Esmagambetov; Irina A Favorskaya; Denis I Zrelkin; Daria V Voronina; Dmitry N Shcherbinin; Alexander S Semikhin; Yana V Simakova; Elizaveta A Tokarskaya; Nadezhda L Lubenets; Daria A Egorova; Maksim M Shmarov; Natalia A Nikitenko; Lola F Morozova; Elena A Smolyarchuk; Evgeny V Kryukov; Vladimir F Babira; Sergei V Borisevich; Boris S Naroditsky; Alexander L Gintsburg
Journal:  Lancet       Date:  2020-09-04       Impact factor: 202.731

View more
  35 in total

Review 1.  Mechanisms of cellular and humoral immunity through the lens of VLP-based vaccines.

Authors:  Hunter McFall-Boegeman; Xuefei Huang
Journal:  Expert Rev Vaccines       Date:  2022-01-24       Impact factor: 5.217

Review 2.  COVID-19 vaccine development: milestones, lessons and prospects.

Authors:  Maochen Li; Han Wang; Lili Tian; Zehan Pang; Qingkun Yang; Tianqi Huang; Junfen Fan; Lihua Song; Yigang Tong; Huahao Fan
Journal:  Signal Transduct Target Ther       Date:  2022-05-03

Review 3.  COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials.

Authors:  Zhi-Peng Yan; Ming Yang; Ching-Lung Lai
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-25

Review 4.  Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19.

Authors:  Hong Zhou; Wei-Jian Ni; Wei Huang; Zhen Wang; Ming Cai; Yan-Cai Sun
Journal:  Front Immunol       Date:  2022-04-05       Impact factor: 8.786

Review 5.  Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease.

Authors:  Tafere Mulaw Belete
Journal:  Infect Drug Resist       Date:  2021-01-19       Impact factor: 4.003

6.  MERS-CoV and SARS-CoV-2 replication can be inhibited by targeting the interaction between the viral spike protein and the nucleocapsid protein.

Authors:  Byoung Kwon Park; Jinsoo Kim; Sangkyu Park; Dongbum Kim; Minyoung Kim; Kyeongbin Baek; Joon-Yong Bae; Man-Seong Park; Won-Keun Kim; Younghee Lee; Hyung-Joo Kwon
Journal:  Theranostics       Date:  2021-02-06       Impact factor: 11.556

7.  A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis.

Authors:  Vasiliki Pappa; Anthi Bouchla; Evangelos Terpos; Thomas P Thomopoulos; Margherita Rosati; Dimitris Stellas; Anastasia Antoniadou; Andreas Mentis; Sotirios G Papageorgiou; Marianna Politou; Anastasia Kotanidou; Ioannis Kalomenidis; Garyfalia Poulakou; Edison Jahaj; Eleni Korompoki; Sotiria Grigoropoulou; Xintao Hu; Jenifer Bear; Sevasti Karaliota; Robert Burns; Maria Pagoni; Ioannis Trontzas; Elisavet Grouzi; Stavroula Labropoulou; Kostantinos Stamoulis; Aristotelis Bamias; Sotirios Tsiodras; Barbara K Felber; George N Pavlakis; Meletios- Athanasios Dimopoulos
Journal:  Microorganisms       Date:  2021-04-11

8.  Evaluation of Antibody Response in Symptomatic and Asymptomatic COVID-19 Patients and Diagnostic Assessment of New IgM/IgG ELISA Kits.

Authors:  Hadeel T Al-Jighefee; Hadi M Yassine; Gheyath K Nasrallah
Journal:  Pathogens       Date:  2021-02-03

Review 9.  Post-Acute COVID-19 Neurological Syndrome: A New Medical Challenge.

Authors:  Domenico Nuzzo; Sonya Vasto; Luca Scalisi; Salvatore Cottone; Gaetano Cambula; Manfredi Rizzo; Daniela Giacomazza; Pasquale Picone
Journal:  J Clin Med       Date:  2021-05-01       Impact factor: 4.241

10.  COVID-19 Vaccine and Death: Causality Algorithm According to the WHO Eligibility Diagnosis.

Authors:  Cristoforo Pomara; Francesco Sessa; Marcello Ciaccio; Francesco Dieli; Massimiliano Esposito; Giovanni Maurizio Giammanco; Sebastiano Fabio Garozzo; Antonino Giarratano; Daniele Prati; Francesca Rappa; Monica Salerno; Claudio Tripodo; Pier Mannuccio Mannucci; Paolo Zamboni
Journal:  Diagnostics (Basel)       Date:  2021-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.